disagree. the stock is trading pathetically less than many other companies that are just in phase 1. this is a small biotech so often these companies are valued on potential, not revenues/earnings. most of these small bios have no revenues or earnings so his assessment is somewhat flawed. the addressable market is enormous and success in phase 2 could send this stock flying. did the author assess the valuation of sage (no approved drugs) or other companies like alny which carried a multi-billion valuation with no approved drugs at the time?
News 
Market Data 
Discover 
